Revance Therapeutics, Inc.
RVNC · NASDAQ
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | $540,865 | $266,947 | $434,777 | $792,385 |
| - Cash | $58,585 | $81,728 | $133,159 | $137,879 |
| + Debt | $483,447 | $491,636 | $475,777 | $478,434 |
| Enterprise Value | $965,727 | $676,855 | $777,395 | $1,132,940 |
| Revenue | $59,879 | $65,389 | $51,936 | $69,799 |
| % Growth | -8.4% | 25.9% | -25.6% | – |
| Gross Profit | $42,246 | $46,325 | $35,044 | $50,908 |
| % Margin | 70.6% | 70.8% | 67.5% | 72.9% |
| EBITDA | -$28,631 | -$30,361 | -$42,288 | -$48,882 |
| % Margin | -47.8% | -46.4% | -81.4% | -70% |
| Net Income | -$35,115 | -$37,473 | -$53,152 | -$55,699 |
| % Margin | -58.6% | -57.3% | -102.3% | -79.8% |
| EPS Diluted | -0.34 | -0.36 | -0.58 | -0.62 |
| % Growth | 5.6% | 37.9% | 6.5% | – |
| Operating Cash Flow | -$41,090 | -$41,128 | -$65,939 | -$42,731 |
| Capital Expenditures | -$61 | -$470 | -$1,712 | -$1,779 |
| Free Cash Flow | -$41,151 | -$41,598 | -$67,651 | -$44,510 |